Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 3/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070627 | 0.87 | BCHE (0.55) | — | |
| SCHEMBL1696017 | 0.85 | MEN1 (0.59) | MEN1KMT2AACP3MEP1BSMN1; SMN2 | |
| SCHEMBL27827175 | 0.85 | MEN1 (0.59) | MEN1KMT2AACP3MEP1BSMN1; SMN2 | |
| SCHEMBL19248981 | 0.85 | MEN1 (0.59) | MEN1KMT2AACP3MEP1BSMN1; SMN2 | |
| SCHEMBL5127277 | 0.84 | CA1 (0.52) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20141045 | 0.82 | MEN1 (0.44) | MEN1KMT2AMEP1B | |
| SCHEMBL5682132 | 0.82 | MAOB (0.52) | — | |
| SCHEMBL10332377 | 0.81 | EPHX1 (0.46) | EPHX1SMN1; SMN2CNR2 | |
| SCHEMBL8187492 | 0.81 | MEN1 (0.55) | MEN1KMT2AACP3MEP1BSMN1; SMN2 | |
| SCHEMBL6202101 | 0.81 | MEP1B (0.57) | MEN1KMT2AACP3MEP1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044186-B9 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARM SPA (IT) | 2006-06-21 | — | — | EP | claimed |
| EP-1044186-B1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARM SPA (IT) | 2006-03-08 | — | — | EP | claimed |
| US-6303819-B1 | SODIUM CHANNEL-BLOCKING AGENT; CHRONIC OR NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-16 | — | — | US | claimed |
| EP-1044186-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-18 | — | — | EP | claimed |
| WO-1999035123-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| EP-1539181-B1 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1795196-A2 | Method of treating lower urinary tract disorders | Dynogen Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | disclosed |
| US-7115606-B2 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1044186-B9 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARM SPA (IT) | 2006-06-21 | — | — | EP | disclosed |
| EP-1044186-B9 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARM SPA (IT) | 2006-06-21 | — | — | EP | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6303819-B1 | SODIUM CHANNEL-BLOCKING AGENT; CHRONIC OR NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-16 | — | — | US | disclosed |
| US-6303819-B1 | SODIUM CHANNEL-BLOCKING AGENT; CHRONIC OR NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-16 | — | — | US | disclosed |
| US-6303819-B1 | SODIUM CHANNEL-BLOCKING AGENT; CHRONIC OR NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-16 | — | — | US | disclosed |
| EP-1044186-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| EP-1044186-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999035123-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035123-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | MEN1 2877/4885KMT2A 2077/4885ACP3 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.